Bharat Biotech International proposes to revive Rs 600 cr Integrated Vaccine ComplexIllustrative image – not actual.
Bharat Biotech International has proposed to partner with the government of Tamil Nadu to revive the Integrated Vaccine Complex (IVC) in the state. The project is struggling to start operations due to cash crunch.

The company has offered to invest in the Rs 600 crore IVC at Chengalpattu, set up by HLL Biotech (HBL), a subsidiary of HLL Lifecare. IVC was conceived in 2008 as a project of national importance to produce vaccines for the National Immunization Programme and make the country self-sufficient.

With a planned annual capacity of 585 million, the project proposed to make pentavalent, or five-in-one, combination vaccine, BCG vaccine, and vaccines to prevent measles, hepatitis B, human rabies, haemophilus influenzae type b (HIB) and Japanese encephalitis (JE) in Phase-I, which was to be commissioned by 2010.

The Ministry of Health is looking at various options including Bharat Biotech’s proposal to revive IVC. Once the ministry takes decision, it will be taken to the cabinet for approval. Bharat Biotech has proposed four vaccine candidates to start with for the collaboration — rotavirus vaccine, JE, rabies vaccine and hepatitis B vaccine.

← All latest storiesBack to top →